Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tg Therapeutics (TGTX) Shares Outstanding (Diluted Average): 2020-2023

Historic Shares Outstanding (Diluted Average) for Tg Therapeutics (TGTX) over the last 2 years, with Jun 2023 value amounting to $141.5 million.

  • Tg Therapeutics' Shares Outstanding (Diluted Average) rose 4.99% to $141.5 million in Q2 2023 from the same period last year, while for Jun 2023 it was $141.5 million, marking a year-over-year increase of 4.99%. This contributed to the annual value of $135.4 million for FY2022, which is 2.41% up from last year.
  • According to the latest figures from Q2 2023, Tg Therapeutics' Shares Outstanding (Diluted Average) is $141.5 million, which was up 0.85% from $140.3 million recorded in Q1 2023.
  • In the past 5 years, Tg Therapeutics' Shares Outstanding (Diluted Average) registered a high of $141.5 million during Q2 2023, and its lowest value of $115.3 million during Q4 2020.
  • Its 3-year average for Shares Outstanding (Diluted Average) is $135.0 million, with a median of $134.6 million in 2022.
  • Data for Tg Therapeutics' Shares Outstanding (Diluted Average) shows a peak YoY grew of 14.64% (in 2021) over the last 5 years.
  • Over the past 4 years, Tg Therapeutics' Shares Outstanding (Diluted Average) (Quarterly) stood at $115.3 million in 2020, then grew by 14.64% to $132.2 million in 2021, then grew by 2.41% to $135.4 million in 2022, then rose by 4.99% to $141.5 million in 2023.
  • Its Shares Outstanding (Diluted Average) stands at $141.5 million for Q2 2023, versus $140.3 million for Q1 2023 and $135.4 million for Q4 2022.